{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:23:49Z","timestamp":1789662229099,"version":"4.0.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["21210710"],"award-info":[{"award-number":["21210710"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consejo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","award":["301832\/2017-0"],"award-info":[{"award-number":["301832\/2017-0"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02014-9","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T12:02:16Z","timestamp":1681560136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review"],"prefix":"10.1007","volume":"40","author":[{"given":"Mar\u00eda","family":"Tosta P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisandra","family":"Herrera Bel\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Letelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-0777","authenticated-orcid":false,"given":"Jorge G.","family":"Far\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"2014_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26391","volume":"64","author":"MM Lins","year":"2017","unstructured":"Lins MM, Santos MO, de Albuquerque MFPM, de Castro CCL, Mello MJG, de Camargo B. Incidence and survival of childhood leukemia in Recife, Brazil: A population-based analysis. Pediatr Blood Cancer. 2017;64:1\u20136. https:\/\/doi.org\/10.1002\/pbc.26391.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10552-015-0657-6","volume":"26","author":"AJ Katz","year":"2015","unstructured":"Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26:1627\u201342. https:\/\/doi.org\/10.1007\/s10552-015-0657-6.","journal-title":"Cancer Causes Control"},{"key":"2014_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.hoc.2009.04.009","volume":"23","author":"M Onciu","year":"2009","unstructured":"Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:655\u201374. https:\/\/doi.org\/10.1016\/j.hoc.2009.04.009.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2014_CR4","unstructured":"McGraw-Hill Interamericana Editores SA de C V, editor. Vademecum Academico de Medicamentos. sexta edic. Mexico: McGraw-Hill Interamericana Editores SA; 2013."},{"key":"2014_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11274-019-2731-9","volume":"35","author":"A Beckett","year":"2019","unstructured":"Beckett A, Gervais D. What makes a good new therapeutic l-asparaginase? World J Microbiol Biotechnol. 2019;35:1\u201313. https:\/\/doi.org\/10.1007\/s11274-019-2731-9.","journal-title":"World J Microbiol Biotechnol"},{"key":"2014_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","volume":"28","author":"HJ M\u00fcller","year":"1998","unstructured":"M\u00fcller HJ, Boos J. Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97\u2013113. https:\/\/doi.org\/10.1016\/S1040-8428(98)00015-8.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2014_CR7","first-page":"241","volume":"1","author":"VI Avramis","year":"2006","unstructured":"Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed. 2006;1:241\u201354.","journal-title":"Int J Nanomed"},{"key":"2014_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s12010-015-1917-3","volume":"178","author":"T Batool","year":"2016","unstructured":"Batool T, Makky EA, Jalal M, Yusoff MM. A comprehensive review on l-asparaginase and its applications. Appl Biochem Biotechnol. 2016;178:900\u201323. https:\/\/doi.org\/10.1007\/s12010-015-1917-3.","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"2014_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1107\/S0907444902019443","volume":"59","author":"J Lubkowski","year":"2003","unstructured":"Lubkowski J. Atomic resolution structure of Erwinia chrysanthemi l-asparaginase. Acta Crystallogr Sect D. 2003;59(1):84\u201392.","journal-title":"Acta Crystallogr Sect D"},{"key":"2014_CR10","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1007\/s12010-012-9755-z","volume":"167","author":"LN Ramya","year":"2012","unstructured":"Ramya LN, Doble M, Rekha VPB, Pulicherla KK. l-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia. Appl Biochem Biotechnol. 2012;167:2144\u201359. https:\/\/doi.org\/10.1007\/s12010-012-9755-z.","journal-title":"Appl Biochem Biotechnol"},{"key":"2014_CR11","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1073\/pnas.90.4.1474","volume":"90","author":"AL Swain","year":"1993","unstructured":"Swain AL, Jaskolski M, Housset D, Rao JKM, Wlodawer A. Crystal structure of Escherichia coli l-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci U S A. 1993;90:1474\u20138. https:\/\/doi.org\/10.1073\/pnas.90.4.1474.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2014_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3109\/07388551.2015.1120705","volume":"37","author":"AM Lopes","year":"2017","unstructured":"Lopes AM, de Oliveira-Nascimento L, Ribeiro A, Tairum CA, Breyer CA, de Oliveira MA, et al. Therapeutic l-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol. 2017;37:82\u201399. https:\/\/doi.org\/10.3109\/07388551.2015.1120705.","journal-title":"Crit Rev Biotechnol"},{"issue":"20","key":"2014_CR13","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2174\/092986710791299920","volume":"17","author":"NE Labrou","year":"2010","unstructured":"Labrou NE, Papageorgiou AC, Avramis VI. Structure\u2013function relationships asparaginases and clinical applications of l-asparaginases. Curr Med Chem. 2010;17(20):2183\u201395.","journal-title":"Curr Med Chem"},{"key":"2014_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.critrevonc.2006.07.009","volume":"61","author":"UK Narta","year":"2007","unstructured":"Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208\u201321. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.07.009.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2014_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.2757","volume":"63","author":"LM Vrooman","year":"2016","unstructured":"Vrooman LM, Kirov II, Dreyer ZE, Kelly M, Hijiya N, Brown P, Drachtman RA, Messinger YH, Ritchey AK, Hale GA, Maloney K, Lu Y, Plourde PV, Silverman LB. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:228\u201333. https:\/\/doi.org\/10.1002\/pbc.2757.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26475","volume":"64","author":"C Ogawa","year":"2017","unstructured":"Ogawa C, Taguchi F, Goto H, Koh K, Tomizawa D, Ohara A, et al. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I\/II clinical trial in Japan. Pediatr Blood Cancer. 2017;64:1\u20138. https:\/\/doi.org\/10.1002\/pbc.26475.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR17","first-page":"1","volume":"2","author":"M Thakur","year":"2014","unstructured":"Thakur M, Lincoln L, Niyonzima FN, Sunil SM. Biotransformation isolation, purification and characterization of fungal. J Biocatal Biotransformation. 2014;2:1\u20139.","journal-title":"J Biocatal Biotransformation"},{"key":"2014_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1054\/bjoc.2001.2000","volume":"85","author":"H Peng","year":"2001","unstructured":"Peng H, Shen N, Qian L, Sun XL, Koduru P, Goodwin LO, et al. Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells. Br J Cancer. 2001;85:930\u20135. https:\/\/doi.org\/10.1054\/bjoc.2001.2000.","journal-title":"Br J Cancer"},{"key":"2014_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.01.002","volume":"100","author":"A Shrivastava","year":"2016","unstructured":"Shrivastava A, Khan AA, Khurshid M, Kalam MA, Jain SK, Singhal PK. Recent developments in l-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol. 2016;100:1\u201310. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.01.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2014_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00280-016-3236-y","volume":"79","author":"C Lanvers-Kaminsky","year":"2017","unstructured":"Lanvers-Kaminsky C. Asparaginase pharmacology: Challenges still to be faced. Cancer Chemother Pharmacol. 2017;79:439\u201350. https:\/\/doi.org\/10.1007\/s00280-016-3236-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2014_CR21","first-page":"111","volume":"91","author":"A Zeidan","year":"2009","unstructured":"Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Drug Eval. 2009;91(9):111\u20139.","journal-title":"Drug Eval"},{"issue":"2","key":"2014_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/10428194.2013.796047","volume":"55","author":"K Kumar","year":"2013","unstructured":"Kumar K, Kaur J, Walia S, Pathak T, Aggarwal D. L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2013;55(2):256\u201362. https:\/\/doi.org\/10.3109\/10428194.2013.796047.","journal-title":"Leuk Lymphoma"},{"key":"2014_CR23","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.blre.2020.100651","volume":"43","author":"TA Costa-Silva","year":"2020","unstructured":"Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva C, Pessoa A, et al. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Rev. 2020;43:100651. https:\/\/doi.org\/10.1016\/j.blre.2020.100651.","journal-title":"Blood Rev"},{"key":"2014_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1017\/cbo9781139107563.069","volume":"6","author":"AL Atienza","year":"2016","unstructured":"Atienza AL. Leucemias Leucemia linfobl\u00e1stica. Pediatr Integr. 2016;6:380\u20139. https:\/\/doi.org\/10.1017\/cbo9781139107563.069.","journal-title":"Pediatr Integr"},{"key":"2014_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/pbc","volume":"63","author":"Y Matloub","year":"2016","unstructured":"Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Gaynon PS. Outcome of children with standard-risk T-lineage acute lymphoblastic leukemia\u2014comparison. Pediatr Blood Cancer. 2016;63:255\u201361. https:\/\/doi.org\/10.1002\/pbc.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR26","unstructured":"Bened\u00ed J, \u00c1ngeles G\u00f3mez del R\u00edo M. F\u00e1rmacos antineopl\u00e1sicos (I). Farm Salud 2006;20:60\u20134."},{"key":"2014_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gamo.2015.06.007","volume":"14","author":"DU Tamayo-Chuc","year":"2015","unstructured":"Tamayo-Chuc DU, Garza-Gonz\u00e1lez AG. Papel de CYP2B6 y ALDH1A1 en la resistencia farmacol\u00f3gica del meduloblastoma a ciclofosfamida. Gac Mex Oncol. 2015;14:46\u201352. https:\/\/doi.org\/10.1016\/j.gamo.2015.06.007.","journal-title":"Gac Mex Oncol"},{"key":"2014_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.rccan.2015.10.002","volume":"20","author":"L Cuca","year":"2016","unstructured":"Cuca L, Mu\u00f1oz D. Compuestos citot\u00f3xicos de origen vegetal y su relaci\u00f3n con prote\u00ednas inhibidoras de apoptosis (IAP). Rev Colomb Cancerol. 2016;20:124\u201334.","journal-title":"Rev Colomb Cancerol"},{"key":"2014_CR29","doi-asserted-by":"crossref","unstructured":"Guilleme CM, Delgado RF, Navarro JS. Actualizaci\u00f3n del tratamiento con L-asparraginasa en Pediatr\u00eda. An Peditria 2013;79:329e1\u201311.","DOI":"10.1016\/j.anpedi.2013.03.015"},{"key":"2014_CR30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. l-asparaginase treatment in acute lymphoblastic leukemia. Cancer. 2011;117:238\u201349. https:\/\/doi.org\/10.1002\/cncr.25489.","journal-title":"Cancer"},{"key":"2014_CR31","doi-asserted-by":"publisher","unstructured":"Ettinger AR. Pharmacology. J Pediatr Oncol 1995:46\u20138. https:\/\/doi.org\/10.1177\/104345429501200110.","DOI":"10.1177\/104345429501200110"},{"key":"2014_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-017-3492-5","volume":"81","author":"S V\u00f6ller","year":"2018","unstructured":"V\u00f6ller S, Pichlmeier U, Zens A, Hempel G. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2018;81:305\u201314. https:\/\/doi.org\/10.1007\/s00280-017-3492-5.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2014_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/ijh-2016-0002","volume":"5","author":"X Thomas","year":"2016","unstructured":"Thomas X, Le Jeune C. Erythrocyte encapsulated l -asparaginase (GRASPA) in acute leukemia. Int J Hematol Oncol. 2016;5:11\u201325. https:\/\/doi.org\/10.2217\/ijh-2016-0002.","journal-title":"Int J Hematol Oncol"},{"key":"2014_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CCO.0b013e32835d7d85","volume":"25","author":"C Rizzari","year":"2013","unstructured":"Rizzari C, Conter V, Star\u00fd J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:1\u20139. https:\/\/doi.org\/10.1097\/CCO.0b013e32835d7d85.","journal-title":"Curr Opin Oncol"},{"key":"2014_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"RP Garay","year":"2012","unstructured":"Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319\u201323. https:\/\/doi.org\/10.1517\/17425247.2012.720969.","journal-title":"Expert Opin Drug Deliv"},{"key":"2014_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","volume":"33","author":"J Kurtzberg","year":"2011","unstructured":"Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a children\u2019s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33:610\u20136. https:\/\/doi.org\/10.1097\/MPH.0b013e31822d4d4e.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2014_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/10428199309149129","volume":"10","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, Holmes R, Lerner S, Ho DH. l-asparaginase and PEG asparaginase\u2014past, present, and future. Leuk Lymphoma. 1993;10:153\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2014_CR38","doi-asserted-by":"publisher","unstructured":"Vieira Pinheiro JP, M\u00fcller HJ, Schwabe D, Gunkel M, Casimiro Da Palma J, Henze G, et al. Drug monitoring of low-dose PEG-asparaginase (OncasparTM) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001;113:115\u20139. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02680.x.","DOI":"10.1046\/j.1365-2141.2001.02680.x"},{"key":"2014_CR39","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","volume":"75","author":"LJ Ettinger","year":"1995","unstructured":"Ettinger LJ, Kurtzberg J, Vo\u01d4te PA, J\u00fcrgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-l-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75:1176\u201381. https:\/\/doi.org\/10.1002\/1097-0142(19950301)75:5%3c1176::AID-CNCR2820750519%3e3.0.CO;2-Y.","journal-title":"Cancer"},{"key":"2014_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2018.00212","volume":"6","author":"LP Brumano","year":"2019","unstructured":"Brumano LP, Silva FVS, Costa-Silva TA, Apolinario AC, Santos JHP, Kleingesinds EK, Monteiro G, Rangel-Yagui CO, Benyahia B, Pessoa A Jr. Development of l-asparaginase biobetters: current research status and review of the desirable quality profiles. Bioeng Biotechnol. 2019;6:1\u20139. https:\/\/doi.org\/10.3389\/fbioe.2018.00212.","journal-title":"Bioeng Biotechnol"},{"key":"2014_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/bcj.2014.26","volume":"4","author":"A Masurekar","year":"2014","unstructured":"Masurekar A, Fong C, Hussein A, Revesz T, Hoogerbrugge PM, Love S, et al. The optimal use of PEG-asparaginase in relapsed ALL-Lessons from the ALLR3 clinical trial. Blood Cancer J. 2014;4:4\u20136. https:\/\/doi.org\/10.1038\/bcj.2014.26.","journal-title":"Blood Cancer J"},{"key":"2014_CR42","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","volume":"32","author":"AL Angiolillo","year":"2014","unstructured":"Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children\u2019s oncology group study AALL07P4. J Clin Oncol. 2014;32:3874\u201382. https:\/\/doi.org\/10.1200\/JCO.2014.55.5763.","journal-title":"J Clin Oncol"},{"key":"2014_CR43","unstructured":"Lehmann-horn K, Sagan SA, Bernard CCA, Sobel A, Zamvil SS, Wanna AGB, et al. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please c. Laryngoscope 2014:2\u201331."},{"key":"2014_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.25319","volume":"1","author":"LT Henriksen","year":"2015","unstructured":"Henriksen LT, Harila-Saari A, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;1:1\u20137. https:\/\/doi.org\/10.1002\/pbc.25319.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR45","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","volume":"23","author":"A Pession","year":"2005","unstructured":"Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7161\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.11.411.","journal-title":"J Clin Oncol"},{"key":"2014_CR46","doi-asserted-by":"publisher","unstructured":"Yen HJ, Chang WH, Liu HC, Yeh TC, Hung GY, Wu KH, et al. Outcomes following discontinuation of E. coli L-asparaginase upon severe allergic reactions in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2016;63:665\u201370. https:\/\/doi.org\/10.1002\/pbc.25869.","DOI":"10.1002\/pbc.25869"},{"key":"2014_CR47","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/blood-2011-07-367904","volume":"118","author":"A Willer","year":"2011","unstructured":"Willer A, Ger\u00df J, K\u00f6nig T, Franke D, K\u00fchnel HJ, Henze G, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E. coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118:5774\u201382. https:\/\/doi.org\/10.1182\/blood-2011-07-367904.","journal-title":"Blood"},{"key":"2014_CR48","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"LM Vrooman","year":"2013","unstructured":"Vrooman LM, Stevenson KE, Supko JG, O\u2019Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL. J Clin Oncol. 2013;31:1202\u201310. https:\/\/doi.org\/10.1200\/JCO.2012.43.2070.","journal-title":"J Clin Oncol"},{"key":"2014_CR49","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.bmc.2017.09.016","volume":"26","author":"M Gebauer","year":"2018","unstructured":"Gebauer M, Skerra A. Prospects of PASylation\u00ae for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorg Med Chem. 2018;26:2882\u20137. https:\/\/doi.org\/10.1016\/j.bmc.2017.09.016.","journal-title":"Bioorg Med Chem"},{"key":"2014_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","volume":"153","author":"C Halfon-Domenech","year":"2011","unstructured":"Halfon-Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005\u201301 randomized trial. Br J Haematol. 2011;153:58\u201365. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08588.x.","journal-title":"Br J Haematol"},{"key":"2014_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3923\/ijp.2014.182.199","volume":"10","author":"NEA El-Naggar","year":"2014","unstructured":"El-Naggar NEA, El-Ewasy SM, El-Shweihy NM. Microbial L-asparaginase as a potential therapeutic agent for the treatment of acute lymphoblastic leukemia: the pros and cons. Int J Pharmacol. 2014;10:182\u201399. https:\/\/doi.org\/10.3923\/ijp.2014.182.199.","journal-title":"Int J Pharmacol"},{"key":"2014_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejphar.2015.12.023","volume":"771","author":"U Ali","year":"2016","unstructured":"Ali U, Naveed M, Ullah A, Ali K, Shah SA, Fahad S, et al. L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): a novel approach to target ALL. Eur J Pharmacol. 2016;771:199\u2013210. https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.023.","journal-title":"Eur J Pharmacol"},{"key":"2014_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjh.12016","volume":"159","author":"RA Raja","year":"2012","unstructured":"Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol. 2012;159:18\u201327. https:\/\/doi.org\/10.1111\/bjh.12016.","journal-title":"Br J Haematol"},{"key":"2014_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/pbc.21037","volume":"49","author":"HM Knoderer","year":"2007","unstructured":"Knoderer HM, Robarge J. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007;49:634\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR55","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/MPH.0b013e3181b794e8","volume":"31","author":"J Flores-Calder\u00f3n","year":"2009","unstructured":"Flores-Calder\u00f3n J, Exiga-Gonzal\u00e9z E, Mor\u00e1n-Villota S, Mart\u00edn-Trejo J, Yamamoto-Nagano A. Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. J Pediatr Hematol Oncol. 2009;31:790\u20133. https:\/\/doi.org\/10.1097\/MPH.0b013e3181b794e8.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2014_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1148\/radiol.11110947","volume":"262","author":"RF Thoeni","year":"2012","unstructured":"Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012;262:751\u201364. https:\/\/doi.org\/10.1148\/radiol.11110947.","journal-title":"Radiology"},{"key":"2014_CR57","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99:1986\u201394. https:\/\/doi.org\/10.1182\/blood.V99.6.1986.","journal-title":"Blood"},{"key":"2014_CR58","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","volume":"111","author":"NL Seibel","year":"2008","unstructured":"Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the children\u2019s oncology group. Blood. 2008;111:2548\u201355. https:\/\/doi.org\/10.1182\/blood-2007-02-070342.","journal-title":"Blood"},{"key":"2014_CR59","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","volume":"17","author":"B Wang","year":"2003","unstructured":"Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia. 2003;17:1583\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2403011.","journal-title":"Leukemia"},{"key":"2014_CR60","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.2217\/fon.14.138","volume":"10","author":"MJ Burke","year":"2014","unstructured":"Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Futur Oncol. 2014;10:2615\u201327. https:\/\/doi.org\/10.2217\/fon.14.138.","journal-title":"Futur Oncol"},{"key":"2014_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pbc.26884","volume":"65","author":"CH Pui","year":"2018","unstructured":"Pui CH, Liu Y, Relling MV. How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer. 2018;65:19\u201320. https:\/\/doi.org\/10.1002\/pbc.26884.","journal-title":"Pediatr Blood Cancer"},{"key":"2014_CR62","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780\u20136. https:\/\/doi.org\/10.1200\/JCO.1993.11.9.1780.","journal-title":"J Clin Oncol"},{"key":"2014_CR63","doi-asserted-by":"crossref","unstructured":"Leukemia L, Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, et al. Allergic reactions to E. coli l-asparaginase do not affect outcome in childhood B-precursor acute. J Pediatr Hematol Oncol. 2007;29:627\u201332.","DOI":"10.1097\/MPH.0b013e3181483df1"},{"key":"2014_CR64","doi-asserted-by":"publisher","unstructured":"Vrooman LMGS. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;54:199\u2013205. https:\/\/doi.org\/10.1002\/pbc.22225.","DOI":"10.1002\/pbc.22225"},{"key":"2014_CR65","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","volume":"32","author":"EA Raetz","year":"2010","unstructured":"Raetz EA, Salzer WL. Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554\u201363.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2014_CR66","unstructured":"Jazz Pharmaceuticals I. ERWINAZE [package insert]. Palo Alto, 2014."},{"key":"2014_CR67","doi-asserted-by":"publisher","unstructured":"Paul V. Plourde, Sima Jeha, Nobuko Hijiya, Frank G. Keller, Lewis B. Silverman, Susan R. Rheingold, ZoAnn E. Dreyer, Gary V. Dahl, Taheri Mercedes, Chinglin Lai, and Tim Corn M. Safety profile of asparaginase erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer 2014;61:1232\u20138. https:\/\/doi.org\/10.1002\/pbc.","DOI":"10.1002\/pbc"},{"key":"2014_CR68","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","volume":"123","author":"WH Tong","year":"2014","unstructured":"Tong WH, Pieters R, Kaspers GJL, Te Loo DMWM, Bierings MB, Van Den Bos C, et al. A prospective study on drug monitoring of PEG asparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026\u201333. https:\/\/doi.org\/10.1182\/blood-2013-10-534347.","journal-title":"Blood"},{"key":"2014_CR69","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95\u201301 for children with acute lymphoblastic leukemia. Blood. 2007;109:896\u2013904. https:\/\/doi.org\/10.1182\/blood-2006-06-027714.","journal-title":"Blood"},{"key":"2014_CR70","first-page":"2423","volume":"32","author":"VI Avramis","year":"2012","unstructured":"Avramis VI. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 2012;32:2423\u201337.","journal-title":"Anticancer Res"},{"issue":"5","key":"2014_CR71","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/10428190701292049","volume":"48","author":"B Zalewska-Szewczyk","year":"2007","unstructured":"Zalewska-Szewczyk B, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48(5):931\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2014_CR72","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1097\/MPH.0b013e3182986559","volume":"36","author":"Y Kawahara","year":"2014","unstructured":"Kawahara Y, Morimoto A, Hayase T, Kashii Y, Fukuda T, Momoi MY. Monitoring of anti-l-asparaginase antibody and l-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli l-asparaginase during desensitization courses. J Pediatr Hematol Oncol. 2014;36:2013\u20135. https:\/\/doi.org\/10.1097\/MPH.0b013e3182986559.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2014_CR73","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","volume":"112","author":"R Pieters","year":"2008","unstructured":"Pieters R, Appel I, Kuehnel HJ, Tetzlaff-Fohr I, Pichlmeier U, Van Der Vaart I, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112:4832\u20138. https:\/\/doi.org\/10.1182\/blood-2008-04-149443.","journal-title":"Blood"},{"key":"2014_CR74","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3109\/1040841X.2015.1022505","volume":"42","author":"PR Krishnapura","year":"2016","unstructured":"Krishnapura PR, Belur PD, Subramanya S. A critical review on properties and applications of microbial l-asparaginases. Crit Rev Microbiol. 2016;42:720\u201337. https:\/\/doi.org\/10.3109\/1040841X.2015.1022505.","journal-title":"Crit Rev Microbiol"},{"key":"2014_CR75","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"AA D\u2019souza","year":"2016","unstructured":"D\u2019souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13:1257\u201375. https:\/\/doi.org\/10.1080\/17425247.2016.1182485.","journal-title":"Expert Opin Drug Deliv"},{"key":"2014_CR76","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1691\/ph.2011.1058","volume":"66","author":"S Suri Vasudev","year":"2011","unstructured":"Suri Vasudev S, Ahmad S, Parveen R, Ahmad FJ, Anish CK, Ali M, et al. Formulation of PEG-ylated l-asparaginase loaded poly (lactide-co-glycolide) nanoparticles: Influence of PEGylation on enzyme loading, activity and in vitro release. Pharmazie. 2011;66:956\u201360. https:\/\/doi.org\/10.1691\/ph.2011.1058.","journal-title":"Pharmazie"},{"key":"2014_CR77","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.biortech.2010.07.114","volume":"102","author":"S Kumar","year":"2011","unstructured":"Kumar S, Venkata Dasu V, Pakshirajan K. Purification and characterization of glutaminase-free l-asparaginase from Pectobacterium carotovorum MTCC 1428. Bioresour Technol. 2011;102:2077\u201382. https:\/\/doi.org\/10.1016\/j.biortech.2010.07.114.","journal-title":"Bioresour Technol"},{"key":"2014_CR78","doi-asserted-by":"publisher","unstructured":"Effer B, Lima GM, Cabarca S, Pessoa A, Far\u00edas JG, Monteiro G. L-Asparaginase from E. chrysanthemi expressed in glycoswitch\u00ae: effect of His-Tag fusion on the extracellular expression. Prep Biochem Biotechnol 2019;49:679\u201385. https:\/\/doi.org\/10.1080\/10826068.2019.1599396.","DOI":"10.1080\/10826068.2019.1599396"},{"key":"2014_CR79","doi-asserted-by":"publisher","unstructured":"Nadeem T, Khan MA, Ijaz B, Ahmed N, Rahman Zur, Latif MS, et al. Glycosylation of recombinant anticancer therapeutics in different expression systems with emerging technologies. Cancer Res 2018;78:2787\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0032.","DOI":"10.1158\/0008-5472.CAN-18-0032"},{"key":"2014_CR80","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10637-014-0102-9","volume":"32","author":"WW Chien","year":"2014","unstructured":"Chien WW, Allas S, Rachinel N, Sahakian P, Julien M, Le Beux C, et al. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Invest New Drugs. 2014;32:795\u2013805. https:\/\/doi.org\/10.1007\/s10637-014-0102-9.","journal-title":"Invest New Drugs"},{"key":"2014_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.enzmictec.2013.12.012","volume":"56","author":"J Vidya","year":"2014","unstructured":"Vidya J, Ushasree MV, Pandey A. Effect of surface charge alteration on stability of l-asparaginase II from Escherichia sp. Enzyme Microb Technol. 2014;56:15\u20139. https:\/\/doi.org\/10.1016\/j.enzmictec.2013.12.012.","journal-title":"Enzyme Microb Technol"},{"key":"2014_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2018.00212","volume":"6","author":"LP Brumano","year":"2019","unstructured":"Brumano LP, da Silva FVS, Costa-Silva TA, Apolin\u00e1rio AC, Santos JHPM, Kleingesinds EK, et al. Development of l-asparaginase biobetters: current research status and review of the desirable quality profiles. Front Bioeng Biotechnol. 2019;6:1\u201322. https:\/\/doi.org\/10.3389\/fbioe.2018.00212.","journal-title":"Front Bioeng Biotechnol"},{"key":"2014_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biologicals.2019.03.003","volume":"59","author":"LH Bel\u00e9n","year":"2019","unstructured":"Bel\u00e9n LH, Lissabet JB, de Oliveira R-Y, Effer B, Monteiro G, Pessoa A, et al. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora. Biologicals. 2019;59:47\u201355. https:\/\/doi.org\/10.1016\/j.biologicals.2019.03.003.","journal-title":"Biologicals"},{"key":"2014_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-012-0071-7","volume":"3","author":"S Datta","year":"2013","unstructured":"Datta S, Christena LR, Rajaram YRS. Enzyme immobilization: an overview on techniques and support materials. Biotechnology. 2013;3:1\u20139. https:\/\/doi.org\/10.1007\/s13205-012-0071-7.","journal-title":"Biotechnology"},{"key":"2014_CR85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/07388551.2014.990414","volume":"36","author":"VE Bosio","year":"2016","unstructured":"Bosio VE, Islan GA, Mart\u00ednez YN, Dur\u00e1n N, Castro GR. Nanodevices for the immobilization of therapeutic enzymes. Crit Rev Biotechnol. 2016;36:447\u201364. https:\/\/doi.org\/10.3109\/07388551.2014.990414.","journal-title":"Crit Rev Biotechnol"},{"key":"2014_CR86","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejpb.2013.01.001","volume":"84","author":"CM Keck","year":"2013","unstructured":"Keck CM, M\u00fcller RH. Nanotoxicological classification system (NCS)\u2014a guide for the risk-benefit assessment of nanoparticulate drug delivery systems. Eur J Pharm Biopharm. 2013;84:445\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2013.01.001.","journal-title":"Eur J Pharm Biopharm"},{"key":"2014_CR87","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1021\/acscentsci.8b00168","volume":"4","author":"LD Blackman","year":"2018","unstructured":"Blackman LD, Varlas S, Arno MC, Houston ZH, Fletcher NL, Thurecht KJ, et al. Confinement of therapeutic enzymes in selectively permeable polymer vesicles by polymerization-induced self-assembly (PISA) reduces antibody binding and proteolytic susceptibility. ACS Cent Sci. 2018;4:718\u201323. https:\/\/doi.org\/10.1021\/acscentsci.8b00168.","journal-title":"ACS Cent Sci"},{"key":"2014_CR88","unstructured":"European Medicines Agency. Graspa: Withdrawal of the marketing authorisation application. EMA\/431413\/2018; 2018."},{"key":"2014_CR89","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/bab.1723","volume":"66","author":"K Torres-Obreque","year":"2019","unstructured":"Torres-Obreque K, Meneguetti GP, Cust\u00f3dio D, Monteiro G, Pessoa-Junior A, de Oliveira R-Y. Production of a novel N-terminal PEGylated crisantaspase. Biotechnol Appl Biochem. 2019;66:281\u20139. https:\/\/doi.org\/10.1002\/bab.1723.","journal-title":"Biotechnol Appl Biochem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02014-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02014-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02014-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:12:47Z","timestamp":1682655167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02014-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2014"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02014-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"150"}}